Motesanib

Search with Google Search with Bing

Information
Drug Name
Motesanib
Description
Entry(CIViC)
2
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
thyroid gland medullary carcinoma RET p.Cys634Trp (p.C634W)
( ENST00000713926.1, ENST00000340058.6, ENST00000615310.5, ENST00000355710.8 ) RET p.Cys634Trp (p.C634W)
( ENST00000340058.6, ENST00000355710.8, ENST00000615310.5, ENST00000713926.1 ) 		D Predictive Supports Resistance Somatic 3 21422803 Detail
thyroid gland medullary carcinoma RET p.Met918Thr (p.M918T)
( ENST00000340058.6, ENST00000713926.1, ENST00000355710.8, ENST00000615310.5 ) RET p.Met918Thr (p.M918T)
( ENST00000340058.6, ENST00000355710.8, ENST00000615310.5, ENST00000713926.1 ) 		D Predictive Supports Resistance Somatic 3 21422803 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Medullary thyroid cancer cells with RET C634W muta... RET RET p.Cys634Trp (p.C634W)
( ENST00000713926.1, ENST00000340058.6, ENST00000615310.5, ENST00000355710.8 ) RET p.Cys634Trp (p.C634W)
( ENST00000340058.6, ENST00000355710.8, ENST00000615310.5, ENST00000713926.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Medullary thyroid cancer cells with RET M918T muta... RET RET p.Met918Thr (p.M918T)
( ENST00000340058.6, ENST00000713926.1, ENST00000355710.8, ENST00000615310.5 ) RET p.Met918Thr (p.M918T)
( ENST00000340058.6, ENST00000355710.8, ENST00000615310.5, ENST00000713926.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT02629848 Terminated Phase 3 Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer July 2012 March 2015
NCT01349088 Withdrawn Phase 1/Phase 2 Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer December 2013 September 2018